Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Keymed Biosciences Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly concentrated prosecution focus for the portfolio at this stage. The presence of only 1 pending action suggests a narrow or early-stage interaction with the patent office in this specific technology sector, requiring precise management of this individual case to ensure successful outcomes.
The busiest examiner for the company is PETRASH, HILARY ANN, who is responsible for the 1 pending office action currently on record. This examiner's workload represents the entirety of the company's pending actions, reflecting a direct and singular point of contact within the patent office for these specific biotechnology and pharmaceutical filings. With 1 distinct art unit involved, the prosecution path remains streamlined under a single administrative division, which allows the company to focus its legal resources on the specific examination standards and preferences of this individual reviewer and their respective unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265114 | DEVELOPMENT OF NEW TUMOR ENGAGER THERAPEUTIC DRUG AND USE THEREOF | HOPKINS, SAMANTHA LAKE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265114 | DEVELOPMENT OF NEW TUMOR ENGAGER THERAPEUTIC DRUG AND USE THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §112DP | Final Rejection | — | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKeymed Biosciences Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samantha Lake Hopkins has the most, with 1 of Keymed Biosciences Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
